NCT05086744View on ClinicalTrials.gov

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

September 20, 2023

Study Completion Date

May 17, 2024

Conditions
Immune Thrombocytopenia (ITP)Cold Agglutinin Disease (CAD)
Interventions
DRUG

Iptacopan

Iptacopan 200 mg BID given orally (capsule)

Trial Locations (8)

20122

Novartis Investigative Site, Milan

28009

Novartis Investigative Site, Madrid

30008

Novartis Investigative Site, Murcia

45147

Novartis Investigative Site, Essen

02114

Massachusetts General Hospital, Boston

06351

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona

W12 0HS

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY